logo
CWCI Examines California's Proposed Presumption for Hospital Worker Injuries & Illnesses

CWCI Examines California's Proposed Presumption for Hospital Worker Injuries & Illnesses

Business Wire11 hours ago
BUSINESS WIRE)--A bill that would give a rebuttable presumption of compensability to a wide range of work injury and illness claims filed by workers who provide direct patient care in California's acute care hospitals would require the hospitals to accept injuries that would normally be denied after investigation and expend significant costs, increase litigation, and set an unsupported precedent by extending presumptions into the private sector according to a California Workers' Compensation Institute (CWCI) analysis.
The analysis shows a lack of evidence supporting the need for hospital worker presumptions, especially given that it would open the door to private sector presumptions.
Share
Unlike other workers' compensation claims, in presumptive injury claims an injured worker does not need to prove that their injury or illness was caused by their job; instead, the employer must prove it was not work-related. Because this is very difficult, rebuttable presumptions have historically been reserved for public safety officers for injuries such as cancer or heart disease that may arise from the unique risks inherent in those public sector jobs, and even then, only when there is clear and compelling evidence of a lack of hazard abatement, a high incidence of injury, and a high claim denial rate. However, SB 632 (Arreguin), now pending in the California Assembly, would extend presumptions into the private sector by granting presumptions to direct care hospital workers for claims involving injuries and illnesses including musculoskeletal injuries, COVID-19 from SARS-CoV-2 and its variants, respiratory diseases (including asthma), cancer, and post-traumatic stress disorder (PTSD).
Using accident year (AY) 2019 – 2024 claims data from its Industry Research Information System (IRIS) database, CWCI's analysis measured the percentage of workers' compensation claims by hospital workers that involved the injuries covered by SB 632 and compared that figure to the percentage of claims from the general workforce that involved those injuries. The Institute then determined the distribution of claims by injury category and calculated the claim denial rates for the hospital worker claims and compared the results to those for the general workforce. Among the findings:
1) 55.7% of all hospital worker claims from AY 2019 - 2024 would be presumptive injuries under SB 632.
2) Of the hospital worker claims, the most common were musculoskeletal injuries (32.1% of all hospital worker claims from the 6-year study period); COVID-19 (21.7%); and respiratory diseases (1.3%). Other injury categories that would be covered by the proposed presumptions together represented less than 1% of the hospital worker claims.
3) Similarly, for the general workforce, the most common injuries covered by SB 632 were musculoskeletal injuries (30.0%), COVID-19 (9.9%), and respiratory diseases (0.8%). As with the hospital worker claims, all other injuries covered by SB 632 represented less than 1% of all general workforce claims.
4) Claim denial rates for injuries and illnesses that would be covered by SB 632 are similar for hospital workers and the general workforce: for hospital workers the claim denial rate was 15.0%; for the general workforce, it was 15.7%. Thus, hospitals accept liability for the injuries at a slightly higher rate than they are accepted in the general workforce.
Workers' compensation presumptions shift the burden of proving that a claim is work-related from the employee to the employer. Because they create exceptions to the grand bargain of workers' compensation, they have been limited to public safety officers for specific injuries that may result from the hazardous conditions associated with those public service jobs, where it is often difficult to safeguard the employee from the dangerous conditions inherent in their work. Such is not the case for hospitals, which have extensive loss control programs and safety procedures. Furthermore, CWCI's analysis found hospitals and the general workforce have similar injury distributions, except for COVID-19 claims, where hospital workers were covered by a presumption during the pandemic. This, combined with nearly identical claim denial rates for hospital worker and general workforce claims involving injuries covered by SB 632, shows a lack of evidence supporting the need for a presumption, especially given that it would open the door to private sector presumptions.
CWCI's Impact Analysis report on SB 632 is available for free under the Research tab at www.cwci.org.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM
Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM

Business Wire

time2 hours ago

  • Business Wire

Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM

TOKYO--(BUSINESS WIRE)--Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has obtained 'Halal Certificate (Certification Number: 355-TSRI/24)' for its functional food ingredient, KANEKA UBIQUINOL TM (active form of coenzyme Q10) powder, under the assessment of Shariah Research Institute of Takushoku University, and issued by JAPAN MUSLIM ASSOCIATION, a religious corporation, on May 28. Halal certification is a system in which relevant organizations verify that products or services do not contain ingredients prohibited under Shariah (Islamic law) and certify their compliance with Shariah. We actively pursue the acquisition of various certifications to ensure the safety and security of our raw materials, and we are pleased to announce that we have obtained a Halal Certificate for KANEKA UBIQUINOL TM. Currently, the Muslim population worldwide is approximately 1.9 billion, and it is estimated to reach 2.2 billion by 2030. In Southeast Asian countries such as Malaysia and Indonesia, where Muslims coexist with people of other faiths, strict standards and regulations have been introduced to ensure the safety and transparency of raw materials used, and the importance of Halal certification is increasing. With the acquisition of this Halal certificate, we expect to expand sales, particularly in Southeast Asia. Based on our mission of KANEKA thinks "Wellness First", we will continue to respond to various needs by providing high-quality products, services and value to make society healthier. Our goal is to enrich people's lives and make society more comfortable in a wide range of fields.

Preceptis Medical Appoints Dave Carey as Chief Executive Officer to Lead Next Phase of Strategic Growth
Preceptis Medical Appoints Dave Carey as Chief Executive Officer to Lead Next Phase of Strategic Growth

Business Wire

time4 hours ago

  • Business Wire

Preceptis Medical Appoints Dave Carey as Chief Executive Officer to Lead Next Phase of Strategic Growth

MINNEAPOLIS--(BUSINESS WIRE)-- Preceptis Medical, Inc., a commercial-stage medical technology company transforming pediatric ENT care, today announced the appointment of Dave Carey as Chief Executive Officer. Carey assumes leadership as the company accelerates toward full market release of its flagship product, the Hummingbird ® Tympanostomy Tube System (TTS). 'We are thrilled to welcome Dave Carey to Preceptis,' said John Seaberg, Chairman of the Board at Preceptis Medical. 'His deep industry expertise, strategic vision, and dedication to improving patient care make him the ideal leader to guide our next phase of growth.' As CEO, Carey will oversee the continued expansion of the Hummingbird TTS System in the U.S., which enables in-office pediatric ear tube placement without the need for general anesthesia. The device has already demonstrated significant clinical, economic, and patient satisfaction benefits in the company's limited market release. 'I'm honored to join the Preceptis Medical team at such an important moment,' said Dave Carey. 'Hummingbird represents a true shift in how we approach pediatric ear tube procedures, and I look forward to partnering with our talented team and surgeon community to bring this solution to more families nationwide.' Preceptis Medical's Hummingbird system enables in-office ear tube placement for young children without the need for general anesthesia, representing a safer, more cost-effective, and family-centered approach to care. For more information, visit

Avvio Medical's Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in
Avvio Medical's Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in

Business Wire

time4 hours ago

  • Business Wire

Avvio Medical's Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in

SAN FRANCISCO--(BUSINESS WIRE)-- Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Study highlights include: The AEROLITH study demonstrated that in the ureteral stone subgroup, a key clinical population, efficacy was comparable between URS-LL with microbubbles and URS-LL alone. However, the use of microbubbles demonstrated a significant safety advantage, including a 42% relative reduction in adverse events. 'This study demonstrates that conventional URS-LL, which currently is the most common surgical procedure to treat stones, yields disappointing results. More than 50% of patients will still have stones after the procedure, with residual fragments large enough to have a high chance for future problems,' stated Wesley Mayer, MD, lead author of the study. 'It is also poorly tolerated, with > 40% of patients reporting adverse events. AEROLITH showed that patients undergoing URS-LL augmented with microbubbles had significantly fewer adverse events, suggesting improved safety and tolerability compared to conventional laser lithotripsy.' These clinical findings further strengthen the growing body of evidence supporting Avvio's proprietary technology. Avvio Medical is also currently evaluating, in a pivotal multi-center clinical trial, the safety and effectiveness of Acoustic Enhancer Microbubbles delivered with its breakthrough Enhanced Lithotripsy System (ELS) utilizing low-intensity therapeutic ultrasound. For more information, visit About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy, enabling kidney stone treatments outside the traditional operating room and into more accessible outpatient settings like ambulatory surgery centers (ASCs), office-based labs (OBLs), and cystoscopy suites. The system delivers a single, minimally invasive therapy without the need for general anesthesia, fluoroscopy, intra-operative imaging, or costly capital equipment. By reducing procedural complexity and resource requirements, ELS supports wider patient access, improves care delivery efficiency, and offers meaningful clinical, economic, and health equity benefits. About Avvio Medical Avvio Medical is a privately held medical technology company based in San Francisco committed to expanding access to safer, more effective urinary stone treatments. By developing minimally invasive solutions that lower costs, reduce reliance on hospital-based care, and remove barriers like general anesthesia and advanced imaging, Avvio aims to improve patient outcomes, drive health system efficiencies, and close gaps in care access across diverse healthcare settings.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store